Risk factors for breast cancer subtypes by race and ethnicity: A scoping review.

IF 9.9 1区 医学 Q1 ONCOLOGY
Amber N Hurson, Thomas U Ahearn, Hela Koka, Brittany D Jenkins, Alexandra R Harris, Sylvia Roberts, Sharon Fan, Jamirra Franklin, Gisela Butera, Renske Keeman, Audrey Y Jung, Pooja Middha, Gretchen L Gierach, Xiaohong R Yang, Jenny Chang-Claude, Rulla M Tamimi, Melissa A Troester, Elisa V Bandera, Mustapha Abubakar, Marjanka K Schmidt, Montserrat Garcia-Closas
{"title":"Risk factors for breast cancer subtypes by race and ethnicity: A scoping review.","authors":"Amber N Hurson, Thomas U Ahearn, Hela Koka, Brittany D Jenkins, Alexandra R Harris, Sylvia Roberts, Sharon Fan, Jamirra Franklin, Gisela Butera, Renske Keeman, Audrey Y Jung, Pooja Middha, Gretchen L Gierach, Xiaohong R Yang, Jenny Chang-Claude, Rulla M Tamimi, Melissa A Troester, Elisa V Bandera, Mustapha Abubakar, Marjanka K Schmidt, Montserrat Garcia-Closas","doi":"10.1093/jnci/djae172","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is comprised of distinct molecular subtypes. Studies have reported differences in risk factor associations with breast cancer subtypes, especially by tumor estrogen receptor (ER) status, but their consistency across racial and ethnic populations has not been comprehensively evaluated.</p><p><strong>Methods: </strong>We conducted a qualitative, scoping literature review using the Preferred Reporting Items for Systematic Reviews and Meta-analysis, extension for Scoping Reviews to investigate consistencies in associations between 18 breast cancer risk factors (reproductive, anthropometric, lifestyle, and medical history) and risk of ER-defined subtypes in women who self-identify as Asian, Black or African American, Hispanic or Latina, or White. We reviewed publications between January 1, 1990 and July 1, 2022. Etiologic heterogeneity evidence (convincing, suggestive, none, or inconclusive) was determined by expert consensus.</p><p><strong>Results: </strong>Publications per risk factor ranged from 14 (benign breast disease history) to 66 (parity). Publications were most abundant for White women, followed by Asian, Black or African American, and Hispanic or Latina women. Etiologic heterogeneity evidence was strongest for parity, followed by age at first birth, post-menopausal BMI, oral contraceptive use, and estrogen-only and combined menopausal hormone therapy. Evidence was limited for other risk factors. Findings were consistent across racial and ethnic groups, although the strength of evidence varied.</p><p><strong>Conclusion: </strong>The literature supports etiologic heterogeneity by ER for some established risk factors that are consistent across race and ethnicity groups. However, in non-White populations evidence is limited. Larger, more comparable data in diverse populations is needed to better characterize breast cancer etiologic heterogeneity.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":null,"pages":null},"PeriodicalIF":9.9000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNCI Journal of the National Cancer Institute","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jnci/djae172","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Breast cancer is comprised of distinct molecular subtypes. Studies have reported differences in risk factor associations with breast cancer subtypes, especially by tumor estrogen receptor (ER) status, but their consistency across racial and ethnic populations has not been comprehensively evaluated.

Methods: We conducted a qualitative, scoping literature review using the Preferred Reporting Items for Systematic Reviews and Meta-analysis, extension for Scoping Reviews to investigate consistencies in associations between 18 breast cancer risk factors (reproductive, anthropometric, lifestyle, and medical history) and risk of ER-defined subtypes in women who self-identify as Asian, Black or African American, Hispanic or Latina, or White. We reviewed publications between January 1, 1990 and July 1, 2022. Etiologic heterogeneity evidence (convincing, suggestive, none, or inconclusive) was determined by expert consensus.

Results: Publications per risk factor ranged from 14 (benign breast disease history) to 66 (parity). Publications were most abundant for White women, followed by Asian, Black or African American, and Hispanic or Latina women. Etiologic heterogeneity evidence was strongest for parity, followed by age at first birth, post-menopausal BMI, oral contraceptive use, and estrogen-only and combined menopausal hormone therapy. Evidence was limited for other risk factors. Findings were consistent across racial and ethnic groups, although the strength of evidence varied.

Conclusion: The literature supports etiologic heterogeneity by ER for some established risk factors that are consistent across race and ethnicity groups. However, in non-White populations evidence is limited. Larger, more comparable data in diverse populations is needed to better characterize breast cancer etiologic heterogeneity.

按种族和民族划分的乳腺癌亚型风险因素:范围综述。
背景:乳腺癌由不同的分子亚型组成。有研究报告称,风险因素与乳腺癌亚型的相关性存在差异,尤其是按肿瘤雌激素受体(ER)状态划分,但尚未对不同种族和族裔人群的相关性进行全面评估:我们采用《系统综述和荟萃分析首选报告项目》(Preferred Reporting Items for Systematic Reviews and Meta-analysis)进行了一项定性、范围性文献综述,以调查自我认同为亚裔、黑人或非裔美国人、西班牙裔或拉丁裔美国人或白人女性的 18 种乳腺癌风险因素(生殖、人体测量、生活方式和病史)与 ER 定义亚型风险之间的一致性。我们查阅了 1990 年 1 月 1 日至 2022 年 7 月 1 日期间的出版物。病因异质性证据(令人信服、提示性、无或不确定)由专家共识决定:每个风险因素的文献从 14 篇(良性乳腺疾病史)到 66 篇(奇偶性)不等。白种女性的文献最多,其次是亚裔、黑人或非裔美国人以及西班牙裔或拉丁裔女性。病因异质性证据中,以奇偶性最强,其次是初产年龄、绝经后体重指数、口服避孕药、纯雌激素和联合绝经激素治疗。其他风险因素的证据有限。不同种族和族裔群体的研究结果是一致的,尽管证据的强度有所不同:文献支持一些已确定的风险因素在 ER 方面的病因异质性,这些因素在不同种族和族裔群体中是一致的。然而,非白人群体的证据有限。为了更好地描述乳腺癌病因异质性,需要在不同人群中获得更多更具可比性的数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
17.00
自引率
2.90%
发文量
203
审稿时长
4-8 weeks
期刊介绍: The Journal of the National Cancer Institute is a reputable publication that undergoes a peer-review process. It is available in both print (ISSN: 0027-8874) and online (ISSN: 1460-2105) formats, with 12 issues released annually. The journal's primary aim is to disseminate innovative and important discoveries in the field of cancer research, with specific emphasis on clinical, epidemiologic, behavioral, and health outcomes studies. Authors are encouraged to submit reviews, minireviews, and commentaries. The journal ensures that submitted manuscripts undergo a rigorous and expedited review to publish scientifically and medically significant findings in a timely manner.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信